These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 10528911)
21. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Burger JA; Ghia P; Rosenwald A; Caligaris-Cappio F Blood; 2009 Oct; 114(16):3367-75. PubMed ID: 19636060 [TBL] [Abstract][Full Text] [Related]
22. A summer of change in hematologic malignancies: highlights in B-Cell malignancies from the 2013 ASCO, EHA, and ICML meetings. Cheson BD Clin Adv Hematol Oncol; 2013 Nov; 11(11):748-50. PubMed ID: 24896550 [No Abstract] [Full Text] [Related]
23. Hematology in 2010: New therapies and standard of care in oncology. DeVita VT; Canellos GP Nat Rev Clin Oncol; 2011 Feb; 8(2):67-8. PubMed ID: 21278770 [TBL] [Abstract][Full Text] [Related]
27. Emerging role of target-based therapies for gastrointestinal malignancies. Dragovich T J BUON; 2005; 10(1):15-21. PubMed ID: 17335127 [No Abstract] [Full Text] [Related]
28. A Systematic Review and Meta-Analysis of Rituximab in Antibody-mediated Renal Allograft Rejection. Hychko G; Mirhosseini A; Parhizgar A; Ghahramani N Int J Organ Transplant Med; 2011; 2(2):51-6. PubMed ID: 25013595 [TBL] [Abstract][Full Text] [Related]
33. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma. Roberts JD; Smith MR; Feldman EJ; Cragg L; Millenson MM; Roboz GJ; Honeycutt C; Thune R; Padavic-Shaller K; Carter WH; Ramakrishnan V; Murgo AJ; Grant S Clin Cancer Res; 2006 Oct; 12(19):5809-16. PubMed ID: 17020988 [TBL] [Abstract][Full Text] [Related]
34. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma. Bosly A; Keating MJ; Stasi R; Bradstock K Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588 [TBL] [Abstract][Full Text] [Related]
35. Future strategies toward the cure of indolent B-cell malignancies. New biologic therapies. Rai KR Semin Hematol; 1999 Oct; 36(4 Suppl 5):12-7. PubMed ID: 10528911 [TBL] [Abstract][Full Text] [Related]
36. Future strategies toward the cure of indolent B-cell malignancies. Immune recognition and antiself. Nadler LM Semin Hematol; 1999 Oct; 36(4 Suppl 5):9-11. PubMed ID: 10528910 [TBL] [Abstract][Full Text] [Related]